{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:12:44Z","timestamp":1790230364753,"version":"4.1.0"},"reference-count":248,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1407,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.exphem.2018.05.004","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T05:53:46Z","timestamp":1527314026000},"page":"12-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice"],"prefix":"10.1016","volume":"64","author":[{"given":"Karine","family":"Sii-Felice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Leboulch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-2327","authenticated-orcid":false,"given":"Emmanuel","family":"Payen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2018.05.004_bib0001","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.exphem.2018.05.004_bib0002","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: a neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0003","first-page":"704","article-title":"Inherited haemoglobin disorders: an increasing global health problem","volume":"79","author":"Weatherall","year":"2001","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.exphem.2018.05.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003327","article-title":"Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis","volume":"9","author":"Taylor","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.exphem.2018.05.004_bib0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2141.2008.07085.x","article-title":"Genetic variation and susceptibility to infection: the red cell and malaria","volume":"141","author":"Weatherall","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0006","series-title":"The future of migration: building capacities for change","year":"2010"},{"key":"10.1016\/j.exphem.2018.05.004_bib0007","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2214-109X(13)70150-5","article-title":"Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000","volume":"2","author":"Piel","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.exphem.2018.05.004_bib0008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1750-1172-9-97","article-title":"Haemoglobinopathies in Europe: health & migration policy perspectives","volume":"9","author":"Aguilar Martinez","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.exphem.2018.05.004_bib0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00365510601046557","article-title":"Epidemiology of haemoglobin disorders in Europe: an overview","volume":"67","author":"Modell","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.exphem.2018.05.004_bib0010","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3109\/07853890.2015.1091942","article-title":"Increasing prevalence of thalassemia in America: Implications for primary care","volume":"47","author":"Sayani","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1590\/S1020-49892003000200018","article-title":"Neonatal screening for hemoglobinopathies in Rio de Janeiro, Brazil [Article in Spanish]","volume":"13","author":"Lobo","year":"2003","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0012","first-page":"812","article-title":"Genetics and blood: haemoglobinopathies and clotting disorders","volume":"36","author":"Metcalfe","year":"2007","journal-title":"Aust Fam Physician"},{"key":"10.1016\/j.exphem.2018.05.004_bib0013","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1749-6632.1998.tb10482.x","article-title":"Global epidemiology of hemoglobin disorders","volume":"850","author":"Angastiniotis","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.exphem.2018.05.004_bib0014","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3324\/haematol.2009.017228","article-title":"The life of patients with thalassemia major","volume":"95","author":"Borgna-Pignatti","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0976-0105.177706","article-title":"Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy","volume":"7","author":"Senol","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.exphem.2018.05.004_bib0016","first-page":"193","article-title":"Health related quality of life, depression, anxiety and stress in patients with beta-thalassemia major","volume":"5","author":"Adib-Hajbaghery","year":"2015","journal-title":"Iran J Ped Hematol Oncol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0973-1075.132622","article-title":"Poor health related quality of life among patients of sickle cell disease","volume":"20","author":"Bhagat","year":"2014","journal-title":"Indian J Palliat Care"},{"key":"10.1016\/j.exphem.2018.05.004_bib0018","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/asheducation.V2012.1.290.3798273","article-title":"What is the evidence that hydroxyurea improves health\u2013related quality of life in patients with sickle cell disease?","volume":"2012","author":"Darbari","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Prog"},{"key":"10.1016\/j.exphem.2018.05.004_bib0019","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1590\/S0103-05822013000100005","article-title":"Quality of life in patients with sickle cell disease [Article in English, Portuguese]","volume":"31","author":"Menezes","year":"2013","journal-title":"Rev Paul Pediatr"},{"key":"10.1016\/j.exphem.2018.05.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010\u20132050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12936-017-1787-y","article-title":"World Malaria Report: time to acknowledge Plasmodium knowlesi malaria","volume":"16","author":"Barber","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.exphem.2018.05.004_bib0022","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1475-2875-11-122","article-title":"Malaria resurgence: a systematic review and assessment of its causes","volume":"11","author":"Cohen","year":"2012","journal-title":"Malar J"},{"key":"10.1016\/j.exphem.2018.05.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002319","article-title":"The US president's malaria initiative and under-5 child mortality in sub-Saharan Africa: a difference-in-differences analysis","volume":"14","author":"Jakubowski","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0024","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.hoc.2010.08.010","article-title":"The population genetics and dynamics of the thalassemias","volume":"24","author":"Weatherall","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2018.05.004_bib0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajmg.c.30202","article-title":"Moving up the slippery slope: mandated genetic screening on Cyprus","volume":"151C","author":"Cowan","year":"2009","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.exphem.2018.05.004_bib0026","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1353\/pbm.0.0093","article-title":"Genetic counseling for thalassemia in the Islamic Republic of Iran","volume":"52","author":"Strauss","year":"2009","journal-title":"Perspect Biol Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0027","article-title":"Thalassemia in the United Arab Emirates: Why it can be prevented but not eradicated","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2018.05.004_bib0028","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/bmj.329.7475.1134","article-title":"Iranian national thalassaemia screening programme","volume":"329","author":"Samavat","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.exphem.2018.05.004_bib0029","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.3399\/bjgp11X601325","article-title":"Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study","volume":"61","author":"Bryan","year":"2011","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.exphem.2018.05.004_bib0030","article-title":"The price of mercy: Comment to the paper entitled \u201cPrevention of beta thalassemia in northern Israel: a cost\u2013benefit analysis\u201d by Koren et\u00a0al. recently published in Mediterranean Journal of Hematology and Infectious Diseases","volume":"6","author":"Giordano","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.exphem.2018.05.004_bib0031","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.012","article-title":"Prevention of beta thalassemia in northern Israel: A cost\u2013benefit analysis","volume":"6","author":"Koren","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.exphem.2018.05.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011775","article-title":"The prevention of thalassemia","volume":"3","author":"Cao","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0033","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/03630269.2013.791627","article-title":"Hemoglobinopathy carrier prevalence in the United Arab Emirates: first analysis of the Dubai Health Authority premarital screening program results","volume":"37","author":"Belhoul","year":"2013","journal-title":"Hemoglobin"},{"key":"10.1016\/j.exphem.2018.05.004_bib0034","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bpobgyn.2017.04.003","article-title":"Preconception and prenatal genetic counselling","volume":"42","author":"Ioannides","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamapediatrics.2017.0250","article-title":"Child and Adolescent Health From 1990 to 2015: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study","volume":"171","author":"Kassebaum","year":"2017","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.exphem.2018.05.004_bib0036","unstructured":"European Network for Rare and Congenital Anaemias. Haemoglobinopathies on the move. Is Europe ready? Health and migration policy perspectives. Available at: https:\/\/www.enerca.org\/media\/upload\/arxius\/Training\/Novartis_OncologyReport_2013.pdf."},{"key":"10.1016\/j.exphem.2018.05.004_bib0037","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0038","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/pbc.21028","article-title":"Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan","volume":"48","author":"Chern","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.exphem.2018.05.004_bib0039","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1365-2257.1999.00262.x","article-title":"Lifetime treatment costs of beta\u2013thalassaemia major","volume":"21","author":"Karnon","year":"1999","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/jms.5.3.120","article-title":"Cost\u2013benefit analysis of a national thalassaemia prevention programme in Israel","volume":"5","author":"Ginsberg","year":"1998","journal-title":"J Med Screen"},{"key":"10.1016\/j.exphem.2018.05.004_bib0041","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-0500-3-29","article-title":"Economic burden of beta-thalassemia\/Hb E and betathalassemia major in Thai children","volume":"3","author":"Riewpaiboon","year":"2010","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.exphem.2018.05.004_bib0042","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1185\/03007990802160834","article-title":"Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study","volume":"24","author":"Scalone","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.exphem.2018.05.004_bib0043","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/imj.13084","article-title":"Haemoglobin disorders in Australia: where are we now and where will we be in the future?","volume":"46","author":"Crighton","year":"2016","journal-title":"Int Med J"},{"key":"10.1016\/j.exphem.2018.05.004_bib0044","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ajh.21865","article-title":"ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children","volume":"86","author":"de Montalembert","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0045","first-page":"155","article-title":"Acute clinical events in 299 homozygous sickle cell patients living in France","volume":"65","author":"Neonato","year":"2000","journal-title":"French Study Group on Sickle Cell Disease. Eur J Haematol."},{"key":"10.1016\/j.exphem.2018.05.004_bib0046","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0047","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London","volume":"92","author":"Telfer","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0048","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood-2010-06-293514","article-title":"Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort","volume":"117","author":"Bernaudin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0049","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/pbc.24557","article-title":"Sickle cell disease related mortality in the United States (1999\u20132009)","volume":"60","author":"Hamideh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.exphem.2018.05.004_bib0050","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00277-016-2655-5","article-title":"East Mediterranean\nregion sickle cell disease mortality trial: retrospective multicentercohort analysis of 735 patients","volume":"95","author":"Karacaoglu","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0052","doi-asserted-by":"crossref","first-page":"C55","DOI":"10.12968\/hmed.2016.77.4.C55","article-title":"Update on sickle cell disease","volume":"77","author":"Hay","year":"2016","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.exphem.2018.05.004_bib0053","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/j.semperi.2015.03.008","article-title":"Newborn screening for sickle cell diseases in the United States: A review of data spanning 2 decades","volume":"39","author":"Therrell","year":"2015","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0054","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/(SICI)1098-2272(1996)13:5<501::AID-GEPI6>3.0.CO;2-4","article-title":"Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state","volume":"13","author":"Lorey","year":"1996","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979\u20132005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"key":"10.1016\/j.exphem.2018.05.004_bib0056","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/pbc.25608","article-title":"Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment","volume":"62","author":"Le","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.exphem.2018.05.004_bib0057","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/pbc.24176","article-title":"Health\u2013related quality of life in sickle cell disease: past, present, and future","volume":"59","author":"Panepinto","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.exphem.2018.05.004_bib0058","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1016\/j.amepre.2010.01.004","article-title":"Sickle cell disease\u2013related pediatric medical expenditures in the U.S.","volume":"38","author":"Amendah","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0059","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.hoc.2014.08.009","article-title":"Allogeneic stem cell transplantation for thalassemia major","volume":"28","author":"Mathews","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2018.05.004_bib0060","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA\u2013identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0061","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0062","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2017.014","article-title":"Treosulfan-based conditioning regimen in sibling and alternative donor hematopoietic stem cell transplantation for children with sickle cell disease","volume":"9","author":"Marzollo","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.exphem.2018.05.004_bib0063","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000\u20132010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0064","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bmt.2008.165","article-title":"Quality of life in patients with transfusion\u2013dependent thalassemia after hematopoietic SCT","volume":"42","author":"Cheuk","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2010.09.011","article-title":"Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation","volume":"17","author":"Caocci","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0066","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood-2013-05-502658","article-title":"Long-term health-related quality of life evaluated more than 20years after hematopoietic stem cell transplantation for thalassemia","volume":"122","author":"La Nasa","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0067","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbmt.2014.12.007","article-title":"Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease","volume":"21","author":"Bhatia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0068","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.bbmt.2012.04.002","article-title":"Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable","volume":"18","author":"Matthes-Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0069","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1017\/S0714980809990390","article-title":"Chronic health conditions: changing prevalence in an aging population and some implications for the delivery of health care services","volume":"29","author":"Denton","year":"2010","journal-title":"Canadian Journal on Aging"},{"key":"10.1016\/j.exphem.2018.05.004_bib0070","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/trf.13513","article-title":"Healthcare costs and outcomes of managing beta-thalassemia major over 50years in the United Kingdom","volume":"56","author":"Weidlich","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.exphem.2018.05.004_bib0071","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.bbmt.2009.06.013","article-title":"Chances of finding anHLA-matched sibling: The Saudi experience","volume":"15","author":"Jawdat","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0072","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.bmt.1703887","article-title":"Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies","volume":"31","author":"Krishnamurti","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0073","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/MOH.0000000000000280","article-title":"Transplantation for thalassemia major: alternative donors","volume":"23","author":"Locatelli","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0074","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0075","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2016.048","article-title":"What unrelated hematopoietic stem cell transplantation in thalassemia taught us about transplant immunogenetics","volume":"8","author":"La Nasa","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.exphem.2018.05.004_bib0076","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/08880018.2012.693577","article-title":"Quality of life assessment in hematopoietic stem cell transplantation performed on thalassemia major patients","volume":"29","author":"Uygun","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0077","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.hemonc.2017.05.008","article-title":"Hematopoietic stem cell transplantation for sickle cell anemia: The changing landscape","volume":"10","author":"Kassim","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0078","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0079","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbmt.2018.01.023","article-title":"Unrelated donor transplantation in children with thalassemia using reduced\u2013intensity conditioning: The URTH Trial","volume":"24","author":"Shenoy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(82)90319-1","article-title":"Marrow transplantation for thalassaemia","volume":"2","author":"Thomas","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2018.05.004_bib0081","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0082","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR\u2013Cas9 by inhibition of nonhomologous end joining","volume":"33","author":"Maruyama","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0083","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein\u2013based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0084","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.celrep.2014.02.040","article-title":"Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing","volume":"7","author":"Hendel","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2018.05.004_bib0085","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","article-title":"Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells","volume":"125","author":"Hoban","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0086","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00439-016-1696-0","article-title":"Treating hemoglobinopathies using gene\u2013correction approaches: promises and challenges","volume":"135","author":"Cottle","year":"2016","journal-title":"Hum Genet"},{"key":"10.1016\/j.exphem.2018.05.004_bib0087","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/hum.2016.007","article-title":"Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene","volume":"27","author":"Negre","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0088","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0092-8674(87)90584-8","article-title":"Position-independent, high-level expression of the human beta-globin gene in transgenic mice","volume":"51","author":"Grosveld","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2018.05.004_bib0089","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1073\/pnas.82.19.6384","article-title":"The \u201cbeta-like-globin\u201d gene domain in human erythroid cells","volume":"82","author":"Tuan","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2018.05.004_bib0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bj.2015.10.001","article-title":"Current and future alternative therapies for beta-thalassemia major","volume":"39","author":"de Dreuzy","year":"2016","journal-title":"Biomed J"},{"key":"10.1016\/j.exphem.2018.05.004_bib0091","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1126\/science.1065806","article-title":"Correction of sickle cell disease in transgenic mouse models by gene therapy","volume":"294","author":"Pawliuk","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.05.004_bib0092","doi-asserted-by":"crossref","first-page":"14380","DOI":"10.1073\/pnas.212507099","article-title":"Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells","volume":"99","author":"Imren","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2018.05.004_bib0093","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/35017565","article-title":"Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin","volume":"406","author":"May","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2018.05.004_bib0094","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1182\/blood-2002-10-3305","article-title":"A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer","volume":"101","author":"Rivella","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0095","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/mt.2011.20","article-title":"Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat beta-thalassemia","volume":"19","author":"Ronen","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0096","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1566523214666141127095336","article-title":"Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease","volume":"15","author":"Negre","year":"2015","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0097","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1016\/S0021-9258(19)85857-X","article-title":"Nucleation-controlled aggregation of deoxyhemoglobin S. Participation of hemoglobin A in the aggregation of deoxyhemoglobin S in concentrated phosphate buffer","volume":"255","author":"Adachi","year":"1980","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.05.004_bib0098","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1016\/S0021-9258(19)43870-2","article-title":"Nucleation-controlled aggregation of deoxyhemoglobin S. Participation of hemoglobin F in the aggregation of deoxyhemoglobin S in concentrated phosphate buffer","volume":"255","author":"Adachi","year":"1980","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.05.004_bib0099","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI101267","article-title":"Some properties of human fetal and maternal blood","volume":"20","author":"Darling","year":"1941","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.05.004_bib0100","doi-asserted-by":"crossref","first-page":"9562","DOI":"10.1016\/S0021-9258(17)36918-1","article-title":"Role of gamma 87 Gln in the inhibition of hemoglobin S polymerization by hemoglobin F","volume":"269","author":"Adachi","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.05.004_bib0101","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1196\/annals.1345.007","article-title":"A phase I\/II clinical trial of beta-globin gene therapy for beta-thalassemia","volume":"1054","author":"Bank","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.exphem.2018.05.004_bib0102","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1002\/j.1460-2075.1994.tb06605.x","article-title":"Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure","volume":"13","author":"Leboulch","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2018.05.004_bib0103","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2018.05.004_bib0104","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X\u2013linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.05.004_bib0105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/asheducation.V2012.1.276.3807841","article-title":"Advances in stem cell transplantation and gene therapy in the beta\u2013hemoglobinopathies","volume":"2012","author":"Payen","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Prog"},{"key":"10.1016\/j.exphem.2018.05.004_bib0106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-0-12-386509-0.00006-5","article-title":"Lentivirus vectors in beta-thalassemia","volume":"507","author":"Payen","year":"2012","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0107","first-page":"268","article-title":"Outcomes of gene therapy for beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta globin vector. EHA, Abstract S742","volume":"99","author":"Cavazzana","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0108","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent beta-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0109","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1182\/blood-2011-02-334425","article-title":"3\u2032UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice","volume":"117","author":"Ikeda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0110","unstructured":"bluebird bio. A study evaluating the efficacy and safety of lentiGlobin BB305 drug product in beta-thalassemia major and sickle cell disease. ClinicalTrials.gov Identifier NCT02151526. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02151526."},{"key":"10.1016\/j.exphem.2018.05.004_bib0111","unstructured":"bluebird bio. A study evaluating the safety and efficacy of thelentiGlobin\u00ae BB305 drug product in beta-thalassemia majorsubjects. ClinicalTrials.gov Identifier NCT01745120.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01745120."},{"key":"10.1016\/j.exphem.2018.05.004_bib0112","unstructured":"bluebird bio. A study evaluating the safety and efficacy of the lentiglobin BB305 drug product in severe sickle cell disease. ClinicalTrials.gov Identifier NCT02140554. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02140554."},{"key":"10.1016\/j.exphem.2018.05.004_bib0113","unstructured":"bluebird bio. A study evaluating the efficacy and safety of the lentiGlobin\u00ae BB305 drug product in subjects with transfusion-dependent \u03b2-thalassemia. ClinicalTrials.gov Identifier\nNCT02906202. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02906202?term=hgb207&rank=1."},{"issue":"S1","key":"10.1016\/j.exphem.2018.05.004_bib0114","first-page":"526","article-title":"Result from the HGB-207 (Northstar-2) trial: a phase 3 study to evaluate safety and efficacy of lentiglobin gene therapy for transfusion-dependent-b-thalassemia (TDT) in patients with non-\u03b20\/\u03b20 genotypes. Abstract 526","volume":"130","author":"Walters","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0115","unstructured":"bluebird bio. A study evaluating the efficacy and safety of the lentiGlobin\u00ae BB305 drug product in subjects with transfusion-dependent \u03b2-thalassemia, who have a \u03b20\/\u03b20 genotype. ClinicalTrials.gov Identifier NCT03207009. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03207009."},{"issue":"S2","key":"10.1016\/j.exphem.2018.05.004_bib0117","first-page":"248","article-title":"Update on the first patients with severe hemoglobinopathies treated with lentiglobin gene therapy [Abstract P631]","volume":"102","author":"Ribeil","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0118","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0119","first-page":"4609","article-title":"Longer term follow-up on the first patients with severe hemoglobinopathies treated with lentiglobin gene therapy","volume":"130","author":"Cavazzana","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0120","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1182\/blood.V128.22.1176.1176","article-title":"Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease","volume":"128","author":"Kanter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0121","first-page":"527","article-title":"Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease","volume":"130","author":"Kanter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0122","unstructured":"Memorial Sloan Kettering Cancer Center. \u03b2-Thalassemia major with autologous CD34+ hematopoietic progenitor cells transduced with TNS9.3.55 a lentiviral vector encoding the normal human \u00df-globin gene. ClinicalTrials.gov Identifier NCT01639690. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01639690."},{"key":"10.1016\/j.exphem.2018.05.004_bib0123","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/hum.2016.037","article-title":"Cell and gene therapy for the beta-thalassemias: advances and prospects","volume":"27","author":"Mansilla-Soto","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"S2","key":"10.1016\/j.exphem.2018.05.004_bib0124","first-page":"15","article-title":"Gene therapy for beta thalassemia: initial results from the phase I\/II TIGET-bthal trial of autologous hematopoietic stem cells genetically modified with globe lentiviral vector [Abstract S128]","volume":"102","author":"Marktel","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0125","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2017.06.010","article-title":"Gene therapy approaches to hemoglobinopathies","volume":"31","author":"Ferrari","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2018.05.004_bib0126","first-page":"355","article-title":"Gene therapy for beta thalassemia: preliminary results from the phase I\/II Tiget-bthaltrial of autologous hematopoietic stem cells genetically modified GLOBE lentiviral vector","volume":"130","author":"Marktel","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0127","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2016.57","article-title":"Gene therapy for hemoglobinopathies: tremendous successes and remaining caveats","volume":"24","author":"Malik","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0128","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","article-title":"Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease","volume":"127","author":"Hoban","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0129","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/asheducation-2017.1.278","article-title":"New therapeutic targets in transfusion-dependent and -independent thalassemia","volume":"2017","author":"Cappellini","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Prog"},{"key":"10.1016\/j.exphem.2018.05.004_bib0130","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13543784.2017.1335709","article-title":"Investigational drugs in phase I and phase II clinical trials for thalassemia","volume":"26","author":"Motta","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.exphem.2018.05.004_bib0131","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-4939-7299-9_5","article-title":"Alternative donor\/unrelated donor transplants for the beta-thalassemia and sickle cell disease","volume":"1013","author":"Fitzhugh","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0132","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/sctm.17-0066","article-title":"A universal approach to correct various HBB gene mutations in human stem cells for gene therapy of beta-thalassemia and sickle cell disease","volume":"7","author":"Cai","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0133","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/asheducation-2005.1.31","article-title":"Pathophysiology of beta thalassemia: a guide to molecular therapies","author":"Thein","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Prog"},{"key":"10.1016\/j.exphem.2018.05.004_bib0134","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/10245332.2017.1333246","article-title":"Revisiting beta thalassemia intermedia: past, present, and future prospects","volume":"22","author":"Ben Salah","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.exphem.2018.05.004_bib0135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1185\/03007995.2015.1110128","article-title":"Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management","volume":"32","author":"Vichinsky","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.exphem.2018.05.004_bib0136","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1002\/ajh.24619","article-title":"The heterozygote state for beta-thalassemia detrimentally affects health outcomes","volume":"92","author":"Graffeo","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0137","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/tan.12313","article-title":"Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance","volume":"83","author":"Andreani","year":"2014","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.exphem.2018.05.004_bib0138","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood.V96.10.3624","article-title":"The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major","volume":"96","author":"Centis","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0139","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.2010.031013","article-title":"Quantitatively different red cell\/nucleated cell chimerism in patients with long\u2013term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease","volume":"96","author":"Andreani","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.bmt.1702151","article-title":"Long-term survival ofex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation","volume":"25","author":"Andreani","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0141","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood-2013-06-507178","article-title":"Safe mobilization of CD34+ cells in adults with beta-thalassemia and validation of effective globin gene transfer for clinical investigation","volume":"123","author":"Boulad","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0142","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1525-0016(16)33088-X","article-title":"Clinical outcomes of gene therapy with BB305 lentiviral vector for sickle cell disease and b-thalassemia","volume":"24","author":"Cavazzana","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0143","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V128.22.1175.1175","article-title":"Lentiglobin gene therapy for transfusion-dependent b-thalassemia: update from the Northstar Hgb-204 phase 1\/2 clinical study","volume":"128","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0144","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1128\/jvi.71.8.5871-5877.1997","article-title":"Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A","volume":"71","author":"Aiken","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-4939-3753-0_4","article-title":"Optimized lentiviral transduction protocols by use of a poloxamer enhancer, spinoculation, and scFv-antibody fusions to VSV-G","volume":"1448","author":"Anastasov","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0146","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0006-3495(04)74197-1","article-title":"Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation","volume":"86","author":"Davis","year":"2004","journal-title":"Biophys J"},{"key":"10.1016\/j.exphem.2018.05.004_bib0147","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1006\/mthe.2001.0269","article-title":"Fibronectin fragment CH-296 inhibits apoptosis and enhances ex vivo gene transfer by murine retrovirus and human lentivirus vectors independent of viral tropism in nonhuman primate CD34+ cells","volume":"3","author":"Donahue","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0148","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2144\/03345dd04","article-title":"Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer","volume":"34","author":"Yamada","year":"2003","journal-title":"Biotechniques"},{"key":"10.1016\/j.exphem.2018.05.004_bib0149","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.V126.23.202.202","article-title":"Outcomes of gene therapy for severe sickle disease and beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta AT87Q-globin vector","volume":"126","author":"Cavazzana","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0150","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V128.22.2311.2311","article-title":"Update from the Hgb\u2013205 phase 1\/2 clinical study of lentiglobin gene therapy: sustained clinical benefit in severe hemoglobinopathies","volume":"128","author":"Ribeil","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0151","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood.V126.23.201.201","volume":"126","author":"Walters","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0152","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1182\/blood-2005-10-4047","article-title":"Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down\u2013regulated by cytokines that enhance transduction","volume":"107","author":"Santoni de Sio","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0153","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1634\/stemcells.2007-0705","article-title":"Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells","volume":"26","author":"Santoni de Sio","year":"2008","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2018.05.004_bib0154","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/sj.gt.3302544","article-title":"Silencing p21(Waf1\/Cip1\/Sdi1) expression increases gene transduction efficiency in primitive human hematopoietic cells","volume":"12","author":"Zhang","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0155","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood-2013-12-546218","article-title":"Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0156","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/mt.2014.193","article-title":"Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells","volume":"23","author":"Petrillo","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0157","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.stemcr.2017.02.010","article-title":"Efficient ex vivo engineering and expansion of highly purified human hematopoietic stem and progenitor cell populations for gene therapy","volume":"8","author":"Zonari","year":"2017","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.exphem.2018.05.004_bib0158","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nature02343","article-title":"The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys","volume":"427","author":"Stremlau","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2018.05.004_bib0159","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.05.004_bib0160","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.05.004_bib0161","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein\u00e2\u20ac\u201cBey Abina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.exphem.2018.05.004_bib0162","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1365-2141.2012.09219.x","article-title":"Engraftment defect of cytokine-cultured adult human mobilized CD34(+) cells is related to reduced adhesion to bone marrow niche elements","volume":"158","author":"Kallinikou","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0163","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2011-08-371583","article-title":"Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain","volume":"119","author":"Larochelle","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0164","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.1201219","article-title":"Isolation of single human hematopoietic stem cells capable of long\u2013term multilineage engraftment","volume":"333","author":"Notta","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.05.004_bib0165","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2017.05.023","article-title":"Improving gene therapy efficiency through the enrichment of human hematopoietic stem cells","volume":"25","author":"Masiuk","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0166","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.exphem.2016.04.003","article-title":"Early production of human neutrophils and platelets posttransplant is severely compromised by growth factor exposure","volume":"44","author":"Miller","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0167","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1191536","article-title":"Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells","volume":"329","author":"Boitano","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.05.004_bib0168","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1256337","article-title":"Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self\u2013renewal","volume":"345","author":"Fares","year":"2014","journal-title":"Science"},{"issue":"S1","key":"10.1016\/j.exphem.2018.05.004_bib0169","first-page":"229","article-title":"PGE2 increases lentiviral vector transduction efficiency of human HSC","volume":"24","author":"Heffner","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0170","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2016.103","article-title":"The role of conditioning in hematopoietic stem cell gene therapy","volume":"27","author":"Bernardo","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0172","unstructured":"IRCCS San Raffaele. Gene therapy for transfusion dependent beta-thalassemia (TIGET\u2013BTHAL). Clinicaltrial.gov identifier:\nNCT02453477. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02453477?term=Thalassemia+gene+therapy&rank=1."},{"key":"10.1016\/j.exphem.2018.05.004_bib0174","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/03630269.2017.1323763","article-title":"Evaluation of applying a combination of red cell indexes and formulas to differentiate beta-thalassemia trait from iron deficiency anemia in the Thai population","volume":"41","author":"Pornprasert","year":"2017","journal-title":"Hemoglobin"},{"key":"10.1016\/j.exphem.2018.05.004_bib0175","first-page":"EC31","article-title":"Evaluation of platelet and red blood cell parameters with proposal of modified score as discriminating guide for iron deficiency anemia and beta-thalassemia minor","volume":"10","author":"Chandra","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.exphem.2018.05.004_bib0176","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1096-8652(199706)55:2<83::AID-AJH6>3.0.CO;2-Z","article-title":"Different hematological phenotypes caused by the interaction of triplicated alpha-globin genes and heterozygous beta-thalassemia","volume":"55","author":"Camaschella","year":"1997","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0177","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ajh.2830200303","article-title":"Concomitant inheritance of alpha\u2013thalassemia in beta 0\u2013 thalassemia\/Hb E disease","volume":"20","author":"Winichagoon","year":"1985","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0178","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2141.1993.tb04702.x","article-title":"Severity differences in beta\u2013thalassaemia\/haemoglobin E syndromes: implication of genetic factors","volume":"83","author":"Winichagoon","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0179","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.1981.tb02753.x","article-title":"Interaction between homozygous beta (0) thalassaemia and the Swiss type of hereditary persistence of fetal haemoglobin","volume":"48","author":"Cappellini","year":"1981","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0180","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1016\/S0021-9258(17)40156-6","article-title":"Human beta-globin messenger RNA. III. Nucleotide sequences derived from complementary DNA","volume":"252","author":"Marotta","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.05.004_bib0181","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle\u2013cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2018.05.004_bib0182","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1073\/pnas.90.11.5039","article-title":"Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations","volume":"90","author":"Poillon","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2018.05.004_bib0183","doi-asserted-by":"crossref","first-page":"31563","DOI":"10.1016\/S0021-9258(18)31730-7","article-title":"Role of hydrophobicity of phenylalanine beta 85 and leucine beta 88 in the acceptor pocket for valine beta 6 during hemoglobin S polymerization","volume":"269","author":"Adachi","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.05.004_bib0184","doi-asserted-by":"crossref","first-page":"15992","DOI":"10.1021\/bi9717439","article-title":"Role of beta87 Thr in the beta6 Val acceptor site during deoxy Hb S polymerization","volume":"36","author":"Reddy","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.exphem.2018.05.004_bib0185","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.V87.4.1617.bloodjournal8741617","article-title":"Polymerization of recombinant hemoglobin F gamma E6V and hemoglobin F gamma E6V, gamma Q87T alone, and in mixtures with hemoglobin S","volume":"87","author":"Adachi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0186","doi-asserted-by":"crossref","first-page":"24557","DOI":"10.1074\/jbc.271.40.24557","article-title":"Polymerization of three hemoglobin A2 variants containing Val6 and inhibition of hemoglobin S polymerization by hemoglobin A2","volume":"271","author":"Adachi","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.05.004_bib0187","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1073\/pnas.77.9.5130","article-title":"Solubilization of hemoglobin S by other hemoglobins","volume":"77","author":"Benesch","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2018.05.004_bib0188","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/256667a0","article-title":"Role of hybrid tetramer formation in gelation of haemoglobin S","volume":"256","author":"Bookchin","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2018.05.004_bib0189","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0022-2836(79)90402-9","article-title":"Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins","volume":"133","author":"Sunshine","year":"1979","journal-title":"J Mol Biol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0190","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/227388a0","article-title":"Dependence of the oxygen affinity of blood on the presence of foetal or adult haemoglobin","volume":"227","author":"Maurer","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2018.05.004_bib0191","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ajh.2830060203","article-title":"Sickle cell anemia and trait in southern India: further studies","volume":"6","author":"Brittenham","year":"1979","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0192","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2141.1978.tb05813.x","article-title":"Fetal haemoglobin production and the sickle gene in the oases of Eastern Saudi Arabia","volume":"40","author":"Pembrey","year":"1978","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-88-1-1","article-title":"Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects","volume":"88","author":"Perrine","year":"1978","journal-title":"Ann Int Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0194","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2141.1988.tb07607.x","article-title":"Sickle cell-hereditary persistence of fetal haemoglobin and its differentiation from other sickle cell syndromes","volume":"69","author":"Murray","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.2011.08916.x","article-title":"Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin","volume":"156","author":"Ngo","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0196","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/bjh.12650","article-title":"Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab\u2013Indian haplotype is not benign","volume":"164","author":"Alsultan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0197","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2011-03-325258","article-title":"Fetal hemoglobin in sickle cell anemia","volume":"118","author":"Akinsheye","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0198","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1182\/blood-2003-03-0712","article-title":"Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease","volume":"102","author":"Kean","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0199","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1401731","article-title":"Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia","volume":"371","author":"DeBaun","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ajh.23877","article-title":"Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy","volume":"90","author":"Beverung","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0201","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood-2013-09-528067","article-title":"Fetal hemoglobin in sickle cell anemia: a glass half full?","volume":"123","author":"Steinberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0202","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2008.08.016","article-title":"Stable long-term donor engraftment following reduced\u2013intensity hematopoietic cell transplantation for sickle cell disease","volume":"14","author":"Krishnamurti","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0203","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2007.06803.x","article-title":"Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis","volume":"139","author":"Wu","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0204","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-04-1376","article-title":"Evidence for ineffective erythropoiesis in severe sickle cell disease","volume":"106","author":"Wu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0205","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","article-title":"Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia","volume":"7","author":"Walters","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0206","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0207","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bjh.13860","article-title":"Comment on: negative health implications of sickle cell trait in high income countries: from the football field to the laboratory","volume":"175","author":"Ballas","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0208","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bjh.13363","article-title":"Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory","volume":"170","author":"Key","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0209","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2018.05.004_bib0210","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI61852","article-title":"Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts","volume":"122","author":"Moiani","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.05.004_bib0211","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1172\/JCI62189","article-title":"Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations","volume":"122","author":"Cesana","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.05.004_bib0212","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/gt.2010.163","article-title":"Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction","volume":"18","author":"Charrier","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0213","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/stem.1957","article-title":"Enrichment of human hematopoietic stem\/progenitor cells facilitates transduction for stem cell gene therapy","volume":"33","author":"Baldwin","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2018.05.004_bib0214","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ymthe.2017.10.015","article-title":"Ex vivo selection of transduced hematopoietic stem cells for gene therapy of beta-hemoglobinopathies","volume":"26","author":"Bhukhai","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0215","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1073\/pnas.100082597","article-title":"Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice","volume":"97","author":"Kalberer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2018.05.004_bib0216","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.bbmt.2009.03.014","article-title":"Effect of ex vivo culture of CD34+ bone marrow cells on immune reconstitution of XSCID dogs following allogeneic bone marrow transplantation","volume":"15","author":"Kennedy","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0217","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood.V92.4.1131","article-title":"Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long\u2013term repopulating ability","volume":"92","author":"Tisdale","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0218","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2010-08-303222","article-title":"Polyclonal fluctuation of lentiviral vector\u2013transduced and expanded murine hematopoietic stem cells","volume":"117","author":"Maetzig","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0219","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood.V88.8.3223.bloodjournal8883223","article-title":"CD34+ cell dosepredicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies","volume":"88","author":"Mavroudis","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0220","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2141.1994.tb06744.x","article-title":"Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation","volume":"87","author":"Bensinger","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0221","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V99.8.2726","article-title":"Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling Bone Marrow Transplant","volume":"99","author":"Bittencourt","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0222","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood.V98.12.3221","volume":"98","author":"Zaucha","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0223","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2003-04-1170","article-title":"Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors","volume":"103","author":"Carvallo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0224","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbmt.2016.01.021","article-title":"Low radiation dose and low cell dose increase the risk of graft rejection in a canine hematopoietic stem cell transplantation model","volume":"22","author":"Lange","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.05.004_bib0225","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (r-metHuG-CSF): the first 10 years","volume":"88","author":"Welte","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0226","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0609.1997.tb00947.x","article-title":"Effects of in vivo administration of G-CSF on neutrophil functions in healthy volunteers","volume":"58","author":"Hoglund","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0227","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000083451","article-title":"Effect of cytokines and chemokines on sickle neutrophil adhesion to fibronectin","volume":"113","author":"Assis","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.exphem.2018.05.004_bib0228","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(95)90629-0","article-title":"Molgramostim to treat SS-sickle cell leg ulcers","volume":"345","author":"Pieters","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2018.05.004_bib0229","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(05)60614-9","article-title":"Granulocytosis causing sickle-cell crisis","volume":"351","author":"Abboud","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2018.05.004_bib0230","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1182\/blood.V97.10.3313","article-title":"Fatal sickle cell crisis after granulocyte colony-stimulating factor administration","volume":"97","author":"Adler","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0231","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V97.12.3998","article-title":"Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell\/beta+ thalassemia","volume":"97","author":"Grigg","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0232","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.exphem.2018.05.004_bib0233","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1182\/blood.V128.22.1176.1176","article-title":"Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease","volume":"128","author":"Kanter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0234","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/mt.2011.195","article-title":"Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects","volume":"20","author":"Yannaki","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0235","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1089\/hum.2013.163","article-title":"Hematopoietic stem cell mobilization for gene therapy: superior mobilization by thecombination of granulocyte-colony stimulating factor plus plerixafor in patients with beta-thalassemia major","volume":"24","author":"Yannaki","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.exphem.2018.05.004_bib0236","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2015-03-629618","article-title":"Plerixafor\u202f+\u202fG-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy","volume":"126","author":"Karponi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0237","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcmd.2015.12.008","article-title":"No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice","volume":"57","author":"Choi","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.exphem.2018.05.004_bib0238","unstructured":"Memorial Sloan Kettering Cancer Center. Escalation of plerixafor for mobilization of CD34+ hematopoietic progenitor cells and evaluation of globin gene transfer in patients with sickle cell disease. ClinicalTrials.gov Identifier NCT02193191. https:\/\/clinicaltrials.gov\/show\/NCT02193191."},{"key":"10.1016\/j.exphem.2018.05.004_bib0239","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-3148.2008.00849.x","article-title":"Transfusion\u2013associated iron overload as a predictive factor for poor stem cell mobilization in patients with haematological malignancies","volume":"18","author":"Park","year":"2008","journal-title":"Transfus Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0240","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jca.20246","article-title":"Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation","volume":"25","author":"Ozkurt","year":"2010","journal-title":"J Clin Apher"},{"key":"10.1016\/j.exphem.2018.05.004_bib0241","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2003-08-2800","article-title":"New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years","volume":"104","author":"Sodani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0242","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.blre.2007.10.001","article-title":"Advances in the allogeneic transplantation for thalassemia","volume":"22","author":"Lucarelli","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.exphem.2018.05.004_bib0243","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20131189","article-title":"Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate","volume":"211","author":"Grover","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2018.05.004_bib0244","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3324\/haematol.2015.133637","article-title":"Mathematical modeling reveals differential effects of erythropoietin on proliferation and lineage commitment of human hematopoietic progenitors in early erythroid culture","volume":"101","author":"Ward","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0245","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1684\/bdc.2012.1589","article-title":"A medical-pharmaceutical partnership model as a contributor to the success in conditioning regimen for allogenic hematopoietic stem cell transplantation in adults: a cross\u2013reflection on our organizations [Article in French]","volume":"99","author":"Bourget","year":"2012","journal-title":"Bull Cancer"},{"issue":"S1","key":"10.1016\/j.exphem.2018.05.004_bib0246","first-page":"360","article-title":"Clinical outcomes up to 3years following lentiglobin gene therapy for transfusion-dependent \u03b2-thalassemia in the Northstar Hgb-204 study","volume":"130","author":"Kwiatkowski","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.05.004_bib0247","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood.V130.Suppl_1.990.990","article-title":"Successful plerixafor-mediated mobilization, apheresis, and lntiviral vector transduction of hematopoietic stem cells in patients with severe sickle cell disease","volume":"130","author":"Tisdale","year":"2017","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.exphem.2018.05.004_bib0248","first-page":"335","article-title":"A phase 3 study to evaluate safety and efficacy of lentiglobin gene therapy for transfusion-dependent b-thalassemia in patients with non-b0\/b0 genotypes: the Northstar-2 (HGB-207) trial [Abstract S814]","volume":"102","author":"Walters","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0251","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.V122.21.716.716","article-title":"First US phase I clinical trial of globin gene transfer for the treatment of beta-thalassemia major","volume":"122","author":"Boulad","year":"2013","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.exphem.2018.05.004_bib0252","first-page":"168","article-title":"A phase I\/II study of autologous hematopoietic stem cells genetically modified with globe lentiviral vector for the treatment of transfusion dependent beta-thalassemia","volume":"101","author":"Marktel","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.05.004_bib0253","unstructured":"Children's Hospital Medical Center. Gene transfer for patients with sickle cell disease. ClinicalTrials.gov Identifier: NCT02186418. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02186418."},{"key":"10.1016\/j.exphem.2018.05.004_bib0254","unstructured":"University of California Children's Hospital. Stem cell gene therapy for sickle cell disease. ClinicalTrials.gov Identifier: NCT02247843. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02247843."}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18302649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18302649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:33:51Z","timestamp":1759566831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X18302649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":248,"alternative-id":["S0301472X18302649"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2018.05.004","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2018.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of ISEH -- Society for Hematology and Stem Cells.","name":"copyright","label":"Copyright"}]}}